Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Pratley, RE; Emerson, SS; Franek, E; Gilbert, MP; Marso, SP; McGuire, DK; Pieber, TR; Zinman, B; Hansen, CT; Hansen, MV; Mark, T; Moses, AC; Buse, JB; DEVOTE Study Group.
Cardiovascular safety and severe hypoglycaemia benefit of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: results from DEVOTE (DEVOTE 7).
Diabetes Obes Metab. 2019;
PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Pieber Thomas
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
To describe the risks of cardiovascular (CV) events and severe hypoglycaemia with insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) aged 65 years or older. A total of 7637 patients in DEVOTE - a treat-to-target, randomized, double-blind trial evaluating the CV safety of degludec versus glargine U100, were divided into three age groups (50-64 years: n = 3682, 65-74 years: n = 3136 and ≥75 years: n = 819). Outcomes by overall age group and randomized treatment differences were analysed for major adverse cardiovascular events (MACE), all-cause mortality, severe hypoglycaemia and serious adverse events (SAEs). Patients with increasing age had higher risks of CV death, all-cause mortality and SAEs, and non-significant trends towards higher risks of MACE and severe hypoglycaemia. Treatment effects on the risks of MACE, all-cause mortality, severe hypoglycaemia and SAEs were consistent across the age groups, based on the non-significant interactions between treatment and age with regard to these outcomes. There were higher risks of CV death, all-cause mortality and SAEs, and trends towards higher risks of MACE and severe hypoglycaemia, with increasing age after adjusting for baseline differences. The effects across age groups of degludec versus glargine U100 on MACE, all-cause mortality and severe hypoglycaemia were comparable, suggesting that the risk for MACE as well as all-cause mortality are similar and risk for severe hypoglycaemia is lower with degludec regardless of age (conclusive evidence only up until 74 years of age). This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

© Meduni Graz Impressum